ReviewJournal of clinical medicine2017
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Review in Journal of clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed/Refractory AML.Clinical lymphoma, myeloma & leukemia · 2025Review
- Unveiling the potential of CLL-1: a promising target for AML therapy.Biomarker research · 2025Review
- Sodium diethyldithiocarbamate trihydrate: an effective and selective compound for hematological malignancies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia.The Journal of clinical investigation · 2024Article
- How to Improve Prognostication in Acute Myeloid Leukemia withBiomedicines · 2021Review
- Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.Blood cancer journal · 2021Article
- Clinical Outcomes Based on Measurable Residual Disease Status in Patients with Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2020Article
- Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms.Journal of clinical medicine · 2020Article
- NPM1 Biology in Myeloid Neoplasia.Current hematologic malignancy reports · 2020Review
- Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry.Diagnostics (Basel, Switzerland) · 2020Article
- Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.Journal of clinical medicine · 2020Review
- [Expression ofZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2019Article
- Article
- Minimal/Measurable Residual Disease Monitoring inInternational journal of molecular sciences · 2018Review
- Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.International journal of molecular sciences · 2018Review
- Evaluating measurable residual disease in acute myeloid leukemia.Blood advances · 2018Review
- DNA damage in acute myeloid leukemia patients of Northern Mexico.European journal of histochemistry : EJH · 2017Article
- Methods of Detection of Measurable Residual Disease in AML.Current hematologic malignancy reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden. In this review, we will summarize the results of the major clinical studies evaluating minimal residual disease in acute myeloid leukemia in adults in recent years and address the technical and practical issues still hampering the spread of these techniques outside controlled clinical trials. We will also briefly speculate on future developments and offer our point of view, and a word of caution, on the present use of minimal residual disease measurements in "real-life" practice. Still, as final standardization and diffusion of the methods are sorted out, we believe that minimal residual disease will soon become the new standard for evaluating response in the treatment of acute myeloid leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.